SalaryGuide
AboutPricingBlogFor Employers

Marketing jobs

6 marketing jobs

Lilly logo
4 days ago

Senior Director, Social Media & Content, Global Communications

Lilly

Indianapolis, IN (Remote)Full time$155K/yr – $227K/yr
Lilly logo
7 days ago

Brand Manager Cardiometabolic Health Sweden

Lilly

Maine, USA (Hybrid)Full timekr667K/yr – kr978K/yr
Lilly logo
11 days ago

Senior Director - LillyDirect Marketing Strategy & Growth Acceleration

Lilly

Indianapolis, IN (On-site)Full time$155K/yr – $249K/yr
Lilly logo
3 months ago

Senior Director, Zepbound Consumer Marketing

Lilly

Indianapolis, IN (On-site)Full time$155K/yr – $227K/yr
Lilly logo
5 months ago

Global Marketing Director (P4-P5)

Lilly

Indianapolis, IN (On-site)Full time
Lilly logo
6 months ago

Associate Director, Media Strategy

Lilly

Indianapolis, IN (On-site)Full time$128K/yr – $187K/yr

All marketing roles in the US

Get alerts for this search

All marketing roles in the US

Get alerts for this search

6 jobs
Lilly logo

Senior Director, Social Media & Content, Global Communications

Lilly

Indianapolis, IN (Remote)

$155K/yr - $227K/yrIn-houseFull-timeSenior level10+ years exp.
4 days ago
Lilly logo

Brand Manager Cardiometabolic Health Sweden

Lilly

Maine, USA (Hybrid)

kr667K/yr - kr978K/yrIn-houseFull-timeMid level
7 days ago
Lilly logo

Senior Director - LillyDirect Marketing Strategy & Growth Acceleration

Lilly

Indianapolis, IN (On-site)

$155K/yr - $249K/yrIn-houseFull-timeSenior level5+ years exp.
11 days ago
Lilly logo

Senior Director, Zepbound Consumer Marketing

Lilly

Indianapolis, IN (On-site)

$155K/yr - $227K/yrIn-houseFull-timeSenior level8+ years exp.
3 months ago
Lilly logo

Global Marketing Director (P4-P5)

Lilly

Indianapolis, IN (On-site)

In-houseFull-timeSenior level3+ years exp.
5 months ago
Lilly logo

Associate Director, Media Strategy

Lilly

Indianapolis, IN (On-site)

$128K/yr - $187K/yrIn-houseFull-timeSenior level7+ years exp.
6 months ago
Lilly logo
Lilly

Senior Director, Social Media & Content, Global Communications

Indianapolis, IN (Remote)

$155K/yr – $227K/yrSenior Level10+ years expFull time

Posted 4 days ago

  • Job
  • Company
  • Salaries
  • People
  • Audience
  • News
  • Links

Job Summary

Own and shape Lilly’s social and digital narrative across platforms, lead editorial and content operations, and coordinate with global teams to amplify priority stories while protecting the brand and patient voice.

  • Drive editorial strategy and agile content production for social-first storytelling
  • Build measurement linking content to resonance, sentiment, and reputation

Job Description

Responsibilities

  • Lead the corporate social and digital strategy across current and emerging platforms, ensuring alignment with overall communications and enterprise goals.
  • Lead owned editorial and content strategy and manage an agile content team responsible for producing social-first and social-exclusive storytelling, including long-form content like blogs.
  • Govern the editorial strategy for Lilly’s corporate digital channels (e.g., Lilly.com, Instagram, Facebook, X, LinkedIn, YouTube), establishing and enforcing publishing cadence, voice, and quality standards, in close partnership with the Senior Director, Digital Operations and Planning.
  • Serve as the steward of Lilly's voice across owned channels — ensuring corporate storytelling consistently reflects the brand's human, caring, and empathetic attributes and the "voice of the patient" positioning.
  • Oversee organic and paid digital advertising efforts to strategically amplify priority content and improve reach and engagement.
  • Integrate with the enterprise editorial pipeline and partner with Executive Communications and other teams to bring leadership voice and spokesperson content to life across owned channels.
  • Identify, test, and scale emerging platforms and content formats, proactively redeploying resources as the media landscape shifts.
  • Partner across Global Communications—including Enterprise Communications, Executive Communications and the therapeutic area (TA) teams—to build social media campaigns and tactics that amplify priority narratives, support launches and achievements, and extend reach across markets.
  • Build a measurement framework that connects content to resonance, sentiment, share of voice, and movement on brand-reputation attributes.
  • Ensure corporate content is optimized for both traditional search and LLMs.

Requirements

  • Bachelor’s degree in Communications, Marketing, Public Relations, Journalism, or a related field.
  • 10+ years of dynamic experience in digital and social media strategy and content creation, with a significant portion in a global, corporate, or agency setting.
  • Qualified applicants must be authorized to work in the United States on a full-time basis. Lilly will not provide support for or sponsor work authorization or visas for this role, including but not limited to F-1 CPT, F-1 OPT, F-1 STEM OPT, J-1, H-1B, TN, O-1, E-3, H-1B1, or L-1.

Preferred

  • Experience operating in a fast-paced, high-stakes environment—such as a newsroom, a regulated or healthcare organization, or a high-profile consumer brand—where speed, judgment, and reputation are paramount.
  • Demonstrated expertise in developing and delivering comprehensive corporate social and digital media strategies that drive measurable engagement and brand reputation.
  • Strong understanding of modern communications subject areas, including content strategy, community management, paid social, and emerging platforms.
  • Current point of view on how brands optimize for AI-generated search and answer experiences (GEO/AI search), and a track record of staying ahead of evolving standard processes.
  • Validated ability to lead an agile content engine, managing editorial processes and ensuring high-quality, social-first storytelling.
  • Record of building and growing large, highly engaged audiences and communities at brand or publisher scale.
  • Experience bringing to bear data and analytics to inform social media strategy, optimize content, and demonstrate business impact.
  • Experience working across global, multi-market teams and an understanding of how regional context, culture, and platform behavior shape what resonates with audiences.
  • Comfort navigating brand, legal, and regulatory considerations when publishing at speed in a complex, scrutinized environment.
  • Strong leadership skills with experience leading teams and fostering cross-functional collaboration, particularly with marketing and executive communications.

Benefits

  • Lilly offers a comprehensive benefit program to eligible employees, including eligibility to participate in a company-sponsored 401(k); pension; vacation benefits; eligibility for medical, dental, vision and prescription drug benefits; flexible benefits (e.g., healthcare and/or dependent day care flexible spending accounts); life insurance and death benefits; certain time off and leave of absence benefits; and well-being benefits (e.g., employee assistance program, fitness benefits, and employee clubs and activities).Lilly reserves the right to amend, modify, or terminate its compensation and benefit programs in its sole discretion and Lilly’s compensation practices and guidelines will apply regarding the details of any promotion or transfer of Lilly employees.
Lilly logo

Lilly

🚀 Lilly - La Révolution du Recrutement Automatisé ! 🚀Simplifiez votre sourcing, boostez votre productivité et trouvez les meilleurs talents en un temps record ! 🔍Avec Lilly, vous pouvez : 💡 Automatiser la recherche et la sélection des meilleurs candidats. ⚡ Lancer votre sourcing en moins de 60 secondes. 🎯 Identifier les talents parfaits grâce à une technologie de pointe en IA. 💬 Envoyer des messages personnalisés et engageants automatiquement. 📈 Optimisez vos recrutements et réduisez le temps passé à chercher des candidats.L'essai est 100% gratuit et vous permet de découvrir à quel point votre recrutement peut être plus rapide, intelligent, et efficace.Vous êtes une agence, une start-up, un ESN ou une entreprise en croissance ? Lilly est faite pour vous !💥 Rejoignez la révolution du recrutement dès maintenant ! 💥

1 employees
lilly-recruiter.com

Salaries

Posted range

$155K/yr – $227K/yr

Taken straight from the job posting.

See all Lilly salaries

Marketing Team

Median Tenure
29.8 years
Marketing Roles Posted (Last 30 Days)
3

People

Founders / CEO

Lilly KipLee
Lilly KipLee
CEO and Founder
At the company for 10 years 2 months

HR / Recruitment

Ryan Burke
Ryan Burke
Talent Acquisition - HR Global Recruiting & Staffing
At the company for 35 years 9 months

Headcount Trend

Current headcount: ~1

Recent News

Eli Lilly to build $6 billion Alabama plant as part of US manufacturing push
Dec 10, 2025 • Reuters
Eli Lilly announces $6 billion pharmaceutical manufacturing investment in Huntsville
Dec 9, 2025 • City of Huntsville (.gov)
Governor Ivey Announces Pharmaceutical Giant Lilly Plans $6 Billion Advanced Manufacturing Plant in Huntsville
Dec 9, 2025 • Alabama Governor's Office (.gov)
Eli Lilly Plans $6 Billion Investment, 450 Jobs In Huntsville
Dec 9, 2025 • Huntsville Business Journal
Lilly to build $6 billion facility to manufacture active pharmaceutical ingredients in Alabama
Dec 9, 2025 • Eli Lilly and Company
Eli Lilly to build $6 billion manufacturing plant in Alabama to help make upcoming obesity pill, other drugs
Dec 9, 2025 • CNBC
Lilly to build $6 billion facility to manufacture active pharmaceutical ingredients in Alabama
Dec 9, 2025 • PR Newswire
Lilly and IU to expand access to clinical trials and latest innovative treatments for Hoosiers
Dec 3, 2025 • News at IU
Lilly lowers the price of Zepbound® (tirzepatide) single-dose vials | Eli Lilly and Company
Dec 1, 2025 • Eli Lilly and Company
Eli Lilly unveils new direct-to-employer model for weight loss drugs
Nov 21, 2025 • Fierce Healthcare
Lilly becomes first drugmaker to hit $1 trillion valuation on weight-loss demand
Nov 21, 2025 • Reuters
Lilly announces plans to open Lilly Gateway Labs site in Philadelphia
Nov 19, 2025 • PR Newswire
Lilly and U.S. government agree to expand access to obesity medicines to millions of Americans
Nov 6, 2025 • Eli Lilly and Company
White House announces deals with Eli Lilly, Novo Nordisk to lower drug costs
Nov 6, 2025 • American Hospital Association
Lilly plans to build a new $3 billion facility to boost oral medicine manufacturing capacity in Europe for patients worldwide | Eli Lilly and Company
Nov 3, 2025 • Eli Lilly and Company
Eli Lilly’s weight loss and diabetes drug tops Keytruda as world’s best-selling medicine
Oct 30, 2025 • statnews.com
Lilly reports third-quarter 2025 financial results, highlights R&D pipeline momentum and raises 2025 guidance
Oct 30, 2025 • Eli Lilly and Company
Lilly announces more than $1.2 billion investment in Puerto Rico facility to boost oral medicine manufacturing capacity in the United States | Eli Lilly and Company
Oct 29, 2025 • Eli Lilly and Company
Lilly announces more than $1.2 billion investment in Puerto Rico facility to boost oral medicine manufacturing capacity in the United States
Oct 29, 2025 • PR Newswire
Eli Lilly to invest $1.2 billion in Puerto Rico as part of US manufacturing push
Oct 29, 2025 • Reuters
Lilly partners with NVIDIA to build the industry's most powerful AI supercomputer, supercharging medicine discovery and delivery for patients | Eli Lilly and Company
Oct 28, 2025 • Eli Lilly and Company
Eli Lilly, NVIDIA team up to build pharma’s biggest AI supercomputer
Oct 28, 2025 • statnews.com
Lilly's baricitinib delivered near-complete scalp hair regrowth at one year for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS trial | Eli Lilly and Company
Oct 24, 2025 • Eli Lilly and Company
Lilly's oral GLP-1, orforglipron, demonstrated superior glycemic control in two successful Phase 3 trials, reconfirming its potential as a foundational treatment in type 2 diabetes | Eli Lilly and Company
Oct 15, 2025 • Eli Lilly and Company
Eli Lilly’s strategy in motion: Beyond diabetes and obesity
Sep 24, 2025 • Labiotech.eu
Lilly plans to build a new $6.5 billion facility to manufacture active pharmaceutical ingredients in Texas
Sep 23, 2025 • PR Newswire
Eli Lilly to make weight-loss pill in new $6.5 billion Texas plant
Sep 23, 2025 • Reuters
Governor Abbott Announces New Eli Lilly Manufacturing Investment In Harris County
Sep 23, 2025 • Office of the Texas Governor (.gov)
Lilly plans to build a new $6.5 billion facility to manufacture active pharmaceutical ingredients in Texas
Sep 23, 2025 • Eli Lilly and Company
Lilly's oral GLP-1, orforglipron, demonstrated meaningful weight loss and cardiometabolic improvements in complete ATTAIN-1 results published in The New England Journal of Medicine
Sep 16, 2025 • Eli Lilly and Company
Lilly unveils 1st of 4 new US manufacturing sites with $5B Virginia API plant
Sep 16, 2025 • Fierce Pharma
Drug manufacturer Eli Lilly to build plant in Goochland, create 650 permanent jobs
Sep 16, 2025 • Virginia Mercury
Lilly trial shows weight loss with experimental pill flattens over time
Sep 16, 2025 • Reuters
Lilly launches TuneLab platform to give biotechnology companies access to AI-enabled drug discovery models built through over $1 billion in research investment
Sep 9, 2025 • Eli Lilly and Company
Eli Lilly temporarily halts UK shipments of weight-loss drug Mounjaro
Aug 27, 2025 • Reuters
Lilly's Verzenio® (abemaciclib) increases overall survival in HR+, HER2-, high-risk early breast cancer with two years of therapy | Eli Lilly and Company
Aug 27, 2025 • Eli Lilly and Company
Anne White to Retire as Executive Vice President and President, Lilly Neuroscience
Aug 20, 2025 • Eli Lilly and Company
Lilly shares fall as obesity pill misses expectations in key trial
Aug 7, 2025 • BioPharma Dive
Lilly raises full-year earnings forecasts on surging demand for weight-loss drug
Aug 7, 2025 • Reuters
Lilly's oral GLP-1, orforglipron, delivers weight loss of up to an average of 27.3 lbs in first of two pivotal Phase 3 trials in adults with obesity | Eli Lilly and Company
Aug 7, 2025 • Eli Lilly and Company
Wisconsin offering up to $100M in development incentives to Eli Lilly's Kenosha County project
Aug 5, 2025 • WPR
Lilly's Mounjaro (tirzepatide), a GIP/GLP-1 dual agonist, demonstrated cardiovascular protection in landmark head-to-head trial, reinforcing its benefit in patients with type 2 diabetes and heart disease
Jul 31, 2025 • Eli Lilly and Company
Lilly's Kisunla (donanemab-azbt) showed growing benefit over three years in early symptomatic Alzheimer's disease
Jul 30, 2025 • Eli Lilly and Company
Lilly's Jaypirca (pirtobrutinib), the first and only approved non-covalent (reversible) BTK inhibitor, met its primary endpoint in a head-to-head Phase 3 trial versus Imbruvica (ibrutinib) in CLL/SLL
Jul 29, 2025 • Eli Lilly and Company
Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk | Eli Lilly and Company
Jul 25, 2025 • Eli Lilly and Company
FDA approves updated label for Lilly's Kisunla (donanemab-azbt) with new dosing in early symptomatic Alzheimer's disease | Eli Lilly and Company
Jul 9, 2025 • Eli Lilly and Company
Lilly's once-weekly insulin efsitora alfa demonstrated A1C reduction and a safety profile consistent with daily insulin in multiple Phase 3 trials | Eli Lilly and Company
Jun 22, 2025 • Eli Lilly and Company
Lilly's oral GLP-1, orforglipron, showed compelling efficacy and a safety profile consistent with injectable GLP-1 medicines, in complete Phase 3 results published in The New England Journal of Medicine
Jun 21, 2025 • Eli Lilly and Company
Lilly partners with Camurus in search of a long-lasting obesity drug
Jun 4, 2025 • BioPharma Dive
Lilly presents first clinical data for its investigational, next-generation FRα targeting ADC in platinum-resistant ovarian cancer at the 2025 ASCO Annual Meeting
Jun 2, 2025 • Eli Lilly and Company
Lilly to expand its pain pipeline with acquisition of SiteOne Therapeutics | Eli Lilly and Company
May 27, 2025 • Eli Lilly and Company
Lilly plans to expand Purdue University collaboration with up to a $250 million investment to accelerate pharmaceutical innovation
May 9, 2025 • Purdue University
Lilly reports first-quarter 2025 financial results and highlights pipeline momentum | Eli Lilly and Company
May 1, 2025 • Eli Lilly and Company
Lilly's oral GLP-1, orforglipron, demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines in successful Phase 3 trial
Apr 17, 2025 • Eli Lilly and Company
Experimental Lilly drug cuts genetic heart disease risk factor by 94% in trial
Mar 30, 2025 • Reuters
Lilly’s statement about the CHMP opinion issued for donanemab | Eli Lilly and Company
Mar 28, 2025 • Eli Lilly and Company
Lilly plans to more than double U.S. manufacturing investment since 2020 exceeding $50 billion | Eli Lilly and Company
Feb 26, 2025 • Eli Lilly and Company
Lilly expands US manufacturing build-out with $50B target
Feb 26, 2025 • BioPharma Dive
Lilly launches additional Zepbound vial doses and offers new savings for self-pay patients
Feb 25, 2025 • Eli Lilly and Company
FDA approves Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease, expanding its use to the second major type of inflammatory bowel disease
Jan 15, 2025 • Eli Lilly and Company
Announcement: Andreessen Horowitz Partners with Lilly to Launch First-of-Its-Kind Biotech Ecosystem Fund
Jan 14, 2025 • Andreessen Horowitz
Lilly shares on track for worst day since 2021 after downbeat Zepbound sales forecast
Jan 14, 2025 • Reuters
Lilly to acquire Scorpion Therapeutics' mutant-selective PI3Kα inhibitor program | Eli Lilly and Company
Jan 13, 2025 • Eli Lilly and Company

Links

lilly-recruiter.comLinkedIn